Table 13.
Effects of rTMS on anxiety, depression, and somatization symptoms in patients with FBD.
| Pre-treatment | Post-treatment | χ″ϖαλυε | p value | |
|---|---|---|---|---|
| SAS | 74.804 | <0.001 | ||
| No | 12 (19.05%) | 56 (88.89%) | ||
| Mild | 5 (7.94%) | 7 (11.11%) | ||
| Moderate | 33 (52.38%) | 0 (0) | ||
| Severe | 13 (20.63%) | 0 (0) | ||
| SDS | 82.528 | <0.001 | ||
| No | 9 (14.29%) | 58 (92.06%) | ||
| Mild | 8 (12.70%) | 5 (7.94%) | ||
| Moderate | 31 (49.21%) | 0 (0) | ||
| Severe | 15 (23.81%) | 0 (0) | ||
| SSS | 62.098 | <0.001 | ||
| No | 7 (11.11%) | 49 (77.78%) | ||
| Mild | 24 (38.10%) | 11 (17.46%) | ||
| Moderate | 10 (15.87%) | 3 (4.76%) | ||
| Severe | 22 (34.92%) | 0 (0) |